GlassScriptPhysician profile
Matthew Levi Fowler
NPI 1871910091
$5,169.41
in general payments reported to CMS, 2019-2025
21 companies · $483 in 2025
The $483 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $164 · 2021: $184 · 2022: $531 · 2023: $794 · 2024: $2,890 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Education: $1,500 · Travel and Lodging: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.67 |
| Education | $1,500.00 |
| Travel and Lodging | $1,121.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,648.16 | 2023-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $693.12 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $309.69 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $215.89 | 2022-2025 | |
| Abiomed | $140.90 | 2025 | |
| United Therapeutics Corporation | $124.99 | 2019 | |
| Ani Pharmaceuticals, INC. | $115.88 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $115.78 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.64 | 2021-2024 | Ofev |
| Medtronic Vascular, INC. | $91.62 | 2020 | |
| Amgen INC. | $91.18 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $79.29 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $78.50 | 2022-2023 | Yupelri |
| Pulmonx Corporation | $72.12 | 2020 | |
| Insmed, INC. | $56.83 | 2022-2025 | Arikayce |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $55.63 | 2023-2025 | Inspire |
| Abbvie INC. | $54.85 | 2021-2023 | |
| Secura Bio, INC. | $43.85 | 2025 | Copiktra |
| Merck Sharp & Dohme LLC | $33.66 | 2025 | Keytruda |
| Pfizer INC. | $19.46 | 2023 | |
| Ethicon INC. | $15.37 | 2023 | Monarch Platform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.